← All Cue Biopharma, INC filings

Cue Biopharma, INC Form 4 insider transactions

NASDAQ
CUE
Cue Biopharma, INC
Form 4: Cue Biopharma CEO Daniel Passeri Acquires 400,000 Stock Options
Cue Biopharma's CEO, Daniel Passeri, reports the acquisition of 400,000 stock options exercisable over time.
NASDAQ
CUE
Cue Biopharma, INC
Form 4: Cue Biopharma's Chief Medical Officer Acquires 260,000 Stock Options
Matteo Levisetti, Chief Medical Officer of Cue Biopharma, acquired 260,000 stock options on March 6, 2024, exercisable in installments starting September 6, 2024.